|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
In CAAH, APOE epsilon 2 may interact with putative risk factors for hemorrhage, including antiplatelet/anticoagulant medication, minor head trauma, and hypertension.
|
10818505 |
2000 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
In ApoE4+ women, CIMT was significantly higher in those with poor metabolic phenotype compared with healthy (p = 0.0003) and high blood pressure (p = 0.001) phenotypes.
|
31362877 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
In hypertension, the association between APOE-ε4 and executive function was also only significant in participants with lower CO2 vasoreactivity (P = .005 for APOE by CO2 vasoreactivity).
|
25688603 |
2015 |
|
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
BEFREE |
Importantly, our results indicated a significant association between ApoE promoter methylation and ACI (OR = 16.146; 95% CI, 1.154-225.832; P* < .05; P*: adjusted for age, gender, carotid atherosclerotic plaque, hypertension, HDL-C, homocysteine, and folate) (Table 4).
|
30658954 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
GWASCAT |
Genetic heterogeneity of Alzheimer's disease in subjects with and without hypertension.
|
31055733 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, after restricting our analysis to Asian populations, the contrasts between the risk of hypertension among individuals possessing ApoE epsilon4 vs. epsilon3 and ApoE4/4 vs. ApoE3/3 were positively reinforced, with ORs of 1.97 (95% CI, 0.93 to 4.15; P=0.08) and 2.27 (95% CI, 1.03 to 4.98; P=0.04), respectively.
|
19816504 |
2009 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Further, that APOE4 predisposes the CV to damage by, and exacerbates the effects of, additional risk factors (such as sex, hypertension, and diabetes).
|
26884068 |
2016 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
For ApoE genotypes, compared with ε3/ε3 genotype, genotypes (ε2/ε2 and ε2/ε3) showed a possible association with hypertension (OR = 0.88; 95% CI: 0.79-0.99; P = 0.033), and genotypes (ε3/ε4 and ε4/ε4) had a 2.08-fold risk of developing hypertension (OR = 2.08; 95% CI: 1.58-2.74; P < 0.001).
|
30180966 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Exploratory analyses revealed that the strongest effect of APOE epsilon4 was in subjects age <65 (OR 3.08, CI 1.43 to 6.64), and was stronger in those with hypertension or cardiovascular disease than in those without.
|
15326239 |
2004 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Exploiting Drug-Apolipoprotein E Gene Interactions in Hypertension to Preserve Cognitive Function: The 3-City Cohort Study.
|
30292766 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.
|
20720404 |
2010 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Consecutive outpatients with late-onset AD were assessed for APOE haplotypes and the following potential baseline predictors: gender, schooling, age at dementia onset, lifetime urban living and sanitary conditions, occupational complexity, cognitive and physical activities, cerebrovascular risk factors (obesity, lifetime alcohol use and smoking, length of arterial hypertension, diabetes mellitus, and a dyslipidemic profile), use of a pacemaker, creatinine clearance, body mass index, waist circumference, head traumas with unconsciousness, treated systemic bacterial infections, amount of surgical procedures under general anesthesia, and family history of AD.
|
30149448 |
2018 |
|
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Carriers of the ESR1 p allele had significantly greater declines in logical memory compared to participants with the PP genotype, independent of demographic characteristics (e.g. age), chronic illness (e.g. hypertension), sleep aid usage, hormone levels, apolipoprotein E e4 status and prospective changes in mood, smoking and alcohol consumption.
|
23128795 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Cardiovascular risk factors such as high serum cholesterol, presence of the Apolipoprotein epsilon4 (APOE epsilon4) allele and hypertension, play important roles in the development of Alzheimer's disease.
|
18378224 |
2008 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Black race (hazard ratio [HR], 1.36; 95% CI, 1.21-1.54), older age (HR, 8.06; 95% CI, 6.69-9.72 for participants aged 60-66 years), lower educational attainment (HR, 1.61; 95% CI, 1.28-2.03 for less than a high school education), and APOE ε4 genotype (HR, 1.98; 95% CI, 1.78-2.21) were associated with increased risk of dementia, as were midlife smoking (HR, 1.41; 95% CI, 1.23-1.61), diabetes (HR, 1.77; 95% CI, 1.53-2.04), prehypertension (HR, 1.31; 95% CI, 1.14-1.51), and hypertension (HR, 1.39; 95% CI, 1.22-1.59).
|
28783817 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Analyses included APOE genotype, gender, ethnicity, body mass index, and other potential confounders such as a history of hypertension, smoking, aspirin use, previous stroke, or ischemic heart disease.
|
10449113 |
1999 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
An overall comparison of the ApoE gene alleles ɛ4 with ɛ3 yielded a significant 81% increased risk for hypertension (95% confidence interval (95% CI): 1.41-2.32; P<0.0005).
|
22113353 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Altered FBS was found in 28.3% of the participants, hypertension in 57.6% and APOE4 in 32.0%.
|
30205523 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
A propensity score analysis was used to model the association of APOE with the burden of hypertension across race/ethnic groups.
|
30726504 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
A custom rat and baboon hypertension gene array to compare experimental models.
|
22228705 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure.
|
9531184 |
1998 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population.
|
31559922 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
APOE ɛ4 remained significant (OR: 2.37; 95% CI: 1.37, 4.07), as did hypertension (OR: 0.55; 95% CI: 0.32, 0.93).
|
28578665 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOE genotype significantly modified the associations between both midlife hypertension and cardiovascular disease and decline in language abilities and midlife diabetes and decline in verbal memory, attention, and visuospatial abilities.
|
23601373 |
2013 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein E gene (ApoE) is one such candidate with its common ɛ2/ɛ3/ɛ4 polymorphism ranking high in hypertension association.
|
21228824 |
2011 |